Influx Healthtech IPO: Strong Demand, Moderate Expectations on Debut Day

Influx Healthtech is making its stock market debut today on the NSE SME platform. The company’s IPO, which raised about Rs 58.5 crore at Rs 96 per share, attracted a lot of attention during the subscription period. Investors are now watching to see how it performs on listing day.

 

Here’s what you need to know:

 

The IPO was hugely oversubscribed, with bids coming in at more than 187 times the available shares. Both retail and institutional investors seemed eager to get a piece of the action.

 

In the grey market, the premium is hovering around Rs 20. That means the stock could open at about Rs 116 per share, which is roughly 20% above the issue price. Despite the strong subscription, the listing buzz is described as moderate—so expectations are steady, not sky-high.

 

The IPO included both a fresh issue and an offer for sale, with anchor investors picking up a chunk before the public offer even opened.

 

Influx Healthtech is based in Thane and started in 2020. The company makes a variety of products, from nutraceuticals and cosmetics to veterinary and homecare items, across three manufacturing sites.

 

Financially, the company is on solid ground. Last year’s revenue was just under Rs 105 crore, and profits rose 19% to Rs 13.4 crore. Debt is low, and returns are healthy.

 

The money raised will help Influx expand its manufacturing, especially for nutraceutical and veterinary products, and buy new equipment.

 

Source: Economic Times, Business Standard, Moneycontrol, News18